Imatinib mesylate is the sole BCR–ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML). Indication was based on the STI571 0109 ...

Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months.

Imatinib specifically inhibits the kinase activity of ABL (including BCR-ABL), PDGFRB, and c-KIT. Recently, this compound has shown efficacy in the treatment of chronic myeloid leukemia 7–9 and ...

Imatinib-free survival could be an interesting end point in terms of toxicity and cost of therapy. The study concept of Z9001 was finalized in 2002, at a time when much less data on the biology of ...

That imatinib 800 mg/d induced remissions more rapidly, when compared with the combination of imatinib with IFN-α, supports the efficacy of high-dose imatinib but does not exclude the possibility of a ...

Imatinib has now been used by more than 100,000 patients worldwide, totaling more than 200,000 patient-years of exposure, she noted.

Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of ...

High-dose imatinib or other kinase inhibitors can restore control when tumors become resistant to other treatment. 2,3 With retail prices exceeding $4,500 monthly, however, the cost of these drugs ...

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

However, clinical activity of imatinib in DFSP is striking even in DFSP expressing relatively low amounts of activated PDGFRB. 38, 48 In our trials, we have not studied molecular changes during ...

Imatinib, an oral tyrosine kinase inhibitor, has also been found to mitigate inflammation through inhibition or modulation of pro-inflammatory cytokines, and it can potentially inhibit the ...

The Assessment Group identified 15 studies of imatinib treatment of c-KIT-positive GIST, which included 6 ongoing uncontrolled trials. Four of the uncontrolled trials were only available in abstract ...